INT78889

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 3.41
Pain Relevance 1.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (UGT1A1) endoplasmic reticulum (UGT1A1) enzyme binding (UGT1A1)
Anatomy Link Frequency
liver 2
UGT1A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Buprenorphine 15 100.00 Very High Very High Very High
Bile 2 97.84 Very High Very High Very High
Morphine 4 89.52 High High
Catecholamine 2 80.48 Quite High
Paracetamol 2 71.12 Quite High
cINOD 1 50.00 Quite Low
Opioid 1 43.52 Quite Low
headache 18 5.00 Very Low Very Low Very Low
Pain 12 5.00 Very Low Very Low Very Low
Potency 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Syndrome 5 99.36 Very High Very High Very High
Hyperbilirubinemia 23 97.44 Very High Very High Very High
Liver Disease 4 95.96 Very High Very High Very High
Jaundice 6 95.76 Very High Very High Very High
Hemolysis 2 95.04 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 166 94.84 High High
Hyperglycemia 10 87.16 High High
Neutropenia 38 86.44 High High
Sprains And Strains 15 83.40 Quite High
Toxicity 59 79.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This study demonstrates that the interactions of substrates and inhibitors at the active site of UGT1A1 are complex, yielding both activation and competitive inhibition kinetics.
UGT1A1 Binding (interactions) of
1) Confidence 0.47 Published 2002 Journal Drug Metab. Dispos. Section Abstract Doc Link 12386134 Disease Relevance 0 Pain Relevance 0.15
The present study was designed to study the kinetic interaction of expressed human UGT2B7(Y) or (H), UGT1A1, and UGT1A3 toward 2- and 4-hydroxycatechol estrogens. cDNAs encoding UGT2B7(Y) or (H), UGT1A1, and UGT1A3 were expressed in HK293 cells, and cell homogenates or membrane preparations were used to determine their glucuronidation ability.
UGT1A1 Binding (interaction) of
2) Confidence 0.47 Published 1998 Journal Toxicol. Sci. Section Abstract Doc Link 9848110 Disease Relevance 0 Pain Relevance 0.15
The microsomes were phenotyped by measuring activities of a panel of substrates, both those reported to be conjugated specifically by UGT1A1 or by other UDP glucuronosyltransferase enzymes.
UGT1A1 Binding (conjugated) of
3) Confidence 0.37 Published 2007 Journal Drug Metab. Dispos. Section Abstract Doc Link 17898154 Disease Relevance 0.15 Pain Relevance 0.07
The additional utility of adding UGT1A1 genotype based on the TA indel was ?
UGT1A1 Binding (genotype) of
4) Confidence 0.37 Published 2008 Journal Archives of Drug Information Section Body Doc Link PMC2710994 Disease Relevance 0.09 Pain Relevance 0
We also observed interactions between UGT1A1 [TA](7) promoter repeat polymorphism and CRP tagSNPs -390C>T/A and 90A>T, in which only the homozygous variant CRP genotype was associated with increased risk of adenoma among those with the UGT1A1 6rpt/6rpt genotype (P interaction=0.02 and 0.04 for -390C>T/A and 90A>T, respectively).
UGT1A1 Binding (interactions) of
5) Confidence 0.35 Published 2009 Journal Pharmacogenet. Genomics Section Body Doc Link 19077918 Disease Relevance 0 Pain Relevance 0
The UGT1A1 promoter (TA)(6/7)TAA mutation (UGT1A1*28) resulted in a 28% decrease of BUP glucuronidation V(max) in pooled HLMs but was not statistically associated with glucuronidation rate in 52 individual HLMs.
UGT1A1 Binding (associated) of associated with buprenorphine
6) Confidence 0.34 Published 2010 Journal Drug Metab. Dispos. Section Abstract Doc Link 19841060 Disease Relevance 0 Pain Relevance 0.98
The E3G formation rates were found to segregate by UGT1A1 promoter genotype, with wild-type (TA)6 rates significantly greater than homozygous mutant (TA)7 individuals.
UGT1A1 Binding (segregate) of
7) Confidence 0.33 Published 2000 Journal Pharmacogenetics Section Abstract Doc Link 11186135 Disease Relevance 0 Pain Relevance 0.12
The implementation of UGT1A1*28 genotyping before initiation of antiretroviral therapy would lead to a theoretical 75% reduction in the number of patients experiencing jaundice.42
UGT1A1 Binding (implementation) of associated with jaundice
8) Confidence 0.23 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.86 Pain Relevance 0
UGT1A1 catalyzes the conjugation of hepatic bilirubin and polymorphisms in the promoter region of UGT1A1 are associated with Gilbert's Syndrome (inherited mild, chronic, unconjugated hyperbilirubinemia in the absence of liver disease or overt hemolysis).
UGT1A1 Binding (associated) of in liver associated with liver disease, hyperbilirubinemia, syndrome and hemolysis
9) Confidence 0.18 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC3000369 Disease Relevance 0.98 Pain Relevance 0
Raltegravir is primarily metabolized by UGT1A1.
UGT1A1 Binding (metabolized) of
10) Confidence 0.18 Published 2010 Journal Core evidence Section Body Doc Link PMC2899791 Disease Relevance 0.33 Pain Relevance 0
UGT1A1 catalyzes the conjugation of hepatic bilirubin and polymorphisms in the promoter region of UGT1A1 are associated with Gilbert's Syndrome (inherited mild, chronic, unconjugated hyperbilirubinemia in the absence of liver disease or overt hemolysis).
UGT1A1 Binding (associated) of in liver associated with liver disease, hyperbilirubinemia, syndrome and hemolysis
11) Confidence 0.14 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC3000369 Disease Relevance 1.00 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox